ArticleCell2019
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 422 papers.
0numbers the graph read from it
0cells of the map it votes in
422citing papers in PubMed
25.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
422 citing papers in PubMed, 603 citations in OpenAlex.
- Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.British journal of cancer · 2025Trial
- Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4Blood neoplasia · 2025Trial
- Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy.Oncoimmunology · 2026Article
- Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.Chinese medical journal · 2026Review
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dysbiosis-induced expansion of AXL-positive inflammatory type 3 dendritic cells triggers preclinical autoimmunity.Nature immunology · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- scRNA-Seq in Gastric Cancer Reveals Macrophage-Derived C1q as a Diagnostic Marker.Cancer science · 2026Article
- Past achievements and future perspectives of personalized vaccines and the role of dendritic cells.Immunologic research · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- Clinical significance of CD161Journal for immunotherapy of cancer · 2026Article
- Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy.Pharmaceutics · 2026Article
- CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy.Cancer research communications · 2026Article
- Differential assembly of mouse and human tumor microenvironments.Nature immunology · 2026Article
- PD-1 Inhibits CD4+ TRM-Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Combating respiratory diseases with mucosal vaccines.Journal of virology · 2026Review
- Cellular fragmentation underlies the immunogenicity of irreversible electroporation-mediated tumor cell killing.Bioengineering & translational medicine · 2026Article
362 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Mikhail BinnewiesDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Adriana M MujalDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Joshua L PollackPionyr Immunotherapeutics, San Francisco, CA 94080, USA.
Alexis J CombesDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
Emily A HardisonDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kevin C BarryDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
Jessica TsuiDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
Megan K RuhlandDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kelly KerstenDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Marwan A AbushawishPionyr Immunotherapeutics, San Francisco, CA 94080, USA.
Marko SpasicDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Jonathan P GiurintanoDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Vincent ChanDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
Adil I DaudDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Patrick HaDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Chun J YeInstitute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
Edward W RobertsDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Matthew F KrummelDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: matthew.krummel@ucsf.edu.
University of California, San Francisco · USUniversity of San Francisco · US
Funding
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0MPREDOCTORAL TRAINING IN DEVELOPMENTAL BIOLOGYT32HD007470 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Todd Nystul · 1994 to 2026
$7.7MIntegrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1MThe Tumor Microenvironment Niche of Type I conventional Dendritic CellsR01CA197363 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW F KRUMMEL · 2017 to 2026
$4.5MManipulating collectivity and Niches for Developing CD8 ImmunityR01AI114787 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2015 to 2019
$2.2MLeukocyte Biomarkers for Predicting Human Breast Cancer OutcomesU54CA163123 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M., DALDRUP-LINK, HEIKE ELIZABETH · 2011 to 2015
$2.0MCUTTING EDGE LINEAGE TRACKING OF TUMOR-EDUCATED IMMUNE CELLSR21CA191428 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2015 to 2016
$391kNCI NIH HHS R01 CA197363NCI NIH HHS R21 CA191428NCI NIH HHS U01 CA217864NCI NIH HHS U54 CA163123NIAID NIH HHS R01 AI114787NIAID NIH HHS T32 AI007334NICHD NIH HHS T32 HD007470
Abstract
Differentiation of proinflammatory CD4
Indexed as
AnimalsAntigens, NeoplasmCD4-Positive T-LymphocytesCell DifferentiationCell Line, TumorCytokinesDendritic CellsDiphtheria ToxinForkhead Transcription FactorsHumansLectins, C-TypeLymph NodesLymphocyte ActivationMelanoma, ExperimentalMiceMice, Inbred C57BLAntigens, NeoplasmCytokinesDiphtheria ToxinForkhead Transcription FactorsFoxp3 protein, mouseLectins, C-TypeMGL2 protein, mouseReceptors, ChemokineXC chemokine receptor 1, mouseCD4(+) T cellscheckpoint blockadedendritic cellsimmunotherapyregulatory T cellsT cell primingtumor immunologytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.